…
Pathkey.AI Ltd, a technology company, develops agentic AI solutions in Australia. The company offers Chipforge, an AI-native semiconductor design and verification platform. It also provides Trialkey, an AI platform for clinical-trial design and prediction. The company was formerly known as Opyl Limited and changed its name to Pathkey.AI Ltd in August 2025. Pathkey.AI Ltd was incorporated in 1994 and is based in Sydney, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on Pathkey.ai Ltd (ASX:PKY) is limited; available disclosures do not clearly describe its core products, customers, or financials. If it operates in artificial intelligence or related software, long-term growth may depend on enterprise AI adoption, scalable recurring revenue and successful commercialization, which could appeal to investors seeking early-stage AI exposure but hinge on execution.
Material risks include the company's limited public disclosure and likely early‑stage profile with execution and financing risk, low liquidity, competitive pressures in AI markets, and potential regulatory or technological obsolescence.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -3.86M | -1.45M | -3.13M | -1.73M | -2.30M |
| Net income | -3.65M | -1.45M | -3.13M | -1.73M | -1.73M |
| Selling general administrative | - | 1.32M | 3.32M | 2.67M | 1.07M |
| Selling and marketing expenses | - | - | - | - | 0.06M |
| Gross profit | -2.81M | - | - | - | -0.93M |
| Ebit | -3.86M | - | - | - | -2.29M |
| Ebitda | -3.85M | - | - | - | -2.27M |
| Depreciation and amortization | 0.01M | - | - | - | 0.03M |
| Operating income | -3.86M | -1.67M | -3.23M | -2.33M | -2.33M |
| Other operating expenses | 3.91M | - | - | - | 2.95M |
| Interest expense | - | - | - | - | 0.00M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | - |
| Interest income | - | 0.07M | 0.43M | 0.00M | - |
| Income tax expense | -0.21M | - | - | - | -0.57M |
| Total revenue | 0.05M | 0.03M | 0.40M | 0.62M | 0.62M |
| Total operating expenses | 1.05M | 1.69M | 3.62M | 2.95M | 1.29M |
| Cost of revenue | 2.86M | - | - | - | 1.55M |
| Total other income expense net | -0.00M | - | - | - | 0.03M |
| Net income applicable to common shares | - | -1.45M | -3.13M | -1.73M | - |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 40.31M | 0.51M | 0.41M | 0.71M | 0.71M |
| Intangible assets | 36.73M | - | 0.00M | 0.02M | 0.02M |
| Other current assets | 0.07M | 0.00M | 0.01M | - | -0.33M |
| Total liab | 0.47M | 0.78M | 0.50M | 1.11M | 0.71M |
| Total stockholder equity | 39.84M | -0.27M | -0.09M | -0.40M | 0.27M |
| Other current liab | 0.22M | - | - | - | 0.07M |
| Common stock | 57.97M | 23.64M | 22.50M | 19.92M | 19.27M |
| Retained earnings | -28.55M | -23.91M | -22.59M | -20.32M | -19.37M |
| Other assets | - | 0.00M | 0.01M | - | - |
| Cash | 3.41M | - | - | - | 0.45M |
| Cash and equivalents | - | 0.11M | 0.37M | 0.45M | - |
| Total current liabilities | 0.47M | 0.78M | 0.50M | 1.10M | 0.68M |
| Current deferred revenue | - | - | - | - | 0.13M |
| Net debt | -3.41M | - | - | - | -0.15M |
| Short term debt | - | 0.41M | 0.00M | 0.30M | 0.30M |
| Short long term debt total | - | - | - | - | 0.30M |
| Property plant equipment | - | 0.02M | 0.02M | 0.01M | - |
| Total current assets | 3.57M | 0.50M | 0.39M | 0.67M | 0.67M |
| Short term investments | - | 0.33M | - | - | - |
| Net receivables | 0.09M | 0.06M | 0.01M | 0.22M | 0.22M |
| Accounts payable | 0.26M | - | - | - | 0.17M |
| Accumulated other comprehensive income | 10.42M | - | - | - | 0.37M |
| Non current assets total | 36.74M | - | - | - | 0.04M |
| Long term debt total | - | 0.00M | 0.00M | 0.00M | - |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total cashflows from investing activities | -0.17M | -0.33M | -0.02M | -0.00M | -0.01M |
| Total cash from financing activities | 4.52M | 1.35M | 2.00M | 1.03M | 0.00M |
| Net income | -3.65M | -1.45M | -3.13M | - | - |
| Change in cash | 3.30M | -0.27M | -0.08M | -0.33M | -1.53M |
| Begin period cash flow | 0.11M | 0.37M | 0.45M | - | - |
| End period cash flow | 3.41M | 0.11M | 0.37M | - | - |
| Total cash from operating activities | -1.05M | -1.28M | -2.06M | -1.36M | -1.52M |
| Depreciation | 0.01M | 0.01M | - | - | - |
| Other cashflows from investing activities | -0.06M | - | - | - | - |
| Change to account receivables | -0.03M | -0.05M | 0.23M | - | - |
| Sale purchase of stock | - | - | -0.19M | 0.96M | 0.00M |
| Other cashflows from financing activities | - | - | -0.00M | -0.07M | 0.00M |
| Capital expenditures | 0.00M | 0.00M | 0.02M | 0.00M | 0.01M |
| Change in working capital | -0.15M | -0.17M | -0.07M | 0.61M | 0.36M |
| Other non cash items | 2.75M | 0.33M | 1.15M | - | - |
| Free cash flow | -1.05M | -1.29M | -2.07M | - | - |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PKY Pathkey.ai Ltd |
-0.00 6.67% |
0.01 | - | 7.03 | 425.63 | 0.51 | 445.83 | -0.68 |
| PME Pro Medicus Ltd |
-4.52 2.18% |
202.79 | 81.98 | 106.38 | 83.13 | 43.70 | 74.38 | 95.34 |
| 4DX 4DMEDICAL Ltd |
-0.06 2.53% |
2.31 | - | - | 205.57 | 8.53 | 170.03 | -7.29 |
| CGS Cogstate Ltd |
0.12 3.30% |
3.76 | 33.80 | 27.86 | 9.59 | 6.95 | 6.35 | 19.27 |
| AYA ARTRYA Ltd |
-0.14 3.91% |
3.44 | - | - | 20505.14 | 7.00 | 16927.51 | 0.33 |
Pathkey.AI Ltd, a technology company, develops agentic AI solutions in Australia. The company offers Chipforge, an AI-native semiconductor design and verification platform. It also provides Trialkey, an AI platform for clinical-trial design and prediction. The company was formerly known as Opyl Limited and changed its name to Pathkey.AI Ltd in August 2025. Pathkey.AI Ltd was incorporated in 1994 and is based in Sydney, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Saurabh Jain | CEO & Executive Chairman | NA |
| Mr. Damon Rasheed | CTO & Executive Director | NA |
| Mr. Mark Ziirsen | Chief Financial Officer | 1963 |
| Bernice Averion | Head of Marketing & Communications | NA |
| Mr. Shane Lewis | Vice President of Sales & Partnerships | NA |
| Mr. Matt Hallam | Chief Revenue Officer | NA |
| Mr. Jonathan Hart B.Com., L.L.B. | Company Secretary | 1984 |
| Mr. Damon Rasheed | CTO & Executive Chairman | NA |
| Mr. Damon Rasheed | Founder, CTO & Executive Director | NA |
| Mr. Andrew Farnsworth | Chief Executive Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.